Redeye comments on BioInvent's Q3 2026 report, which was published together with a rights issue of approximately SEK430m, of which 81% is covered by subscription commitments and guarantees. The money will mainly be used to start a randomised Part C triplet study with BI-1808 in platinum-resistant ovarian cancer in Q1 2027. We include dilution from the rights issue in our model and delay the timing of deals and launches, which lowers our Fair Value to SEK24 (SEK75). The BioInvent share screens as "Attractively Priced".
LÄS MER
